Board of Directors
Chairman of the Board
Bengt Ågerup, PhD
Bengt Ågerup is a PhD and has held senior positions within Pharmacia and Biomatrix, and he started the company Q-Med that was subsequently sold to Galderma in 2011. Bengt is the founder of nxt2b, Chairman of Stockholm Uppsala Life Science, and a Board Member of the Swedish Foundation for Strategic Research.
Board Member
Prof. Ulf Landegren
Scientific co-founder of Olink AB and co-founder of ParAllele Bioscience Inc. Prof. Landegren is an internationally recognized scientific leader in molecular detection and amplification technologies, with an established network in the scientific and biotech business communities. Prof. Landegren has authored more than 100 peer-reviewed articles and is the designated inventor of more than 20 patents and patent applications.
Board Member
Prof. Olle Kämpe
Olle Kämpe is Professor of Molecular Medicine at Uppsala University since 1999 and senior consultant in internal medicine and in endocrinology at the University Hospital in Uppsala. He is a fellow of the Royal Swedish Academy of Sciences, appointed by the Swedish Research Council to the board of the Swedish Infrastructure for large scale sequencing (SNISS) and scientific adviser part-time to nxt2b.
Board Member
Prof. Mats Nilsson
Professor and group leader at Rudbeck Laboratory, Uppsala University. Co-founder of Olink AB, Q-linea AB and ParAllele Bioscience Inc. His research is focused on developing single-molecule and single-cell gene analytic techniques, employing advanced molecular tools combined with microscopy and microfluidics. Prof. Nilsson is author of more than 60 peer-reviewed articles, published in leading journals such as Science, Nature Genetics, Nature Biotechnology, Nature Methods, PNAS, Analytical Chemistry and Nucleic Acids Research. He is the designated inventor of 5 patents.
Board member
Håkan Englund
Håkan Englund has more than 30 years of experience from the life science industry and has held several leading positions at Pharmacia Biotech (currently GE HealthCare) and Phadia. At Phadia he has been responsible for commercialization of new business and product areas such as POC and multiplexing within allergy diagnostics. He is presently board member of Uppsala Bio and Uppsala Chamber of Commerce.
Board Member
Björn Ekström
Björn Ekström is co-founder and retiring President and CEO of Olink. He was co-founder and Executive VP of Pyrosequencing AB and part of the IPO team listing the company on Stockholm Stock Exchange in 2000. Prior to that he held several leading positions within Pharmacia Biotech (currently GE HealthCare). Ekström serves on the board of Cobolt AB, Qlinea AB, Sigolis AB, and Halo Genomics AB.